These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

750 related articles for article (PubMed ID: 21440505)

  • 1. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
    Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C
    Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
    Denham JW; Steigler A; Lamb DS; Joseph D; Mameghan H; Turner S; Matthews J; Franklin I; Atkinson C; North J; Poulsen M; Christie D; Spry NA; Tai KH; Wynne C; Duchesne G; Kovacev O; D'Este C;
    Lancet Oncol; 2005 Nov; 6(11):841-50. PubMed ID: 16257791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.
    Bolla M; Van Tienhoven G; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Billiet I; Torecilla JL; Pfeffer R; Cutajar CL; Van der Kwast T; Collette L
    Lancet Oncol; 2010 Nov; 11(11):1066-73. PubMed ID: 20933466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
    Pilepich MV; Winter K; John MJ; Mesic JB; Sause W; Rubin P; Lawton C; Machtay M; Grignon D
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1243-52. PubMed ID: 11483335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
    Crook J; Ludgate C; Malone S; Lim J; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):15-23. PubMed ID: 15337535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
    Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
    Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109.
    Berglund RK; Tangen CM; Powell IJ; Lowe BA; Haas GP; Carroll PR; Canby-Hagino ED; deVere White R; Hemstreet GP; Crawford ED; Thompson IM; Klein EA
    Urology; 2012 Mar; 79(3):633-7. PubMed ID: 22386416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose radiotherapy plus prolonged hormone therapy in CT2-3 prostatic carcinoma: is it useful?
    Cellini N; Pompei L; Fortuna G; Ammaturo MV; De Paula U; Luzi S; Mattiucci GC; Morganti AG; Digesù C; Rosetto ME; Palloni T; Petrongari MG; Gentile P; Deodato F; Valentini V
    Tumori; 2004; 90(2):201-7. PubMed ID: 15237583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiotherapy and short-term androgen deprivation for localized prostate cancer.
    Jones CU; Hunt D; McGowan DG; Amin MB; Chetner MP; Bruner DW; Leibenhaut MH; Husain SM; Rotman M; Souhami L; Sandler HM; Shipley WU
    N Engl J Med; 2011 Jul; 365(2):107-18. PubMed ID: 21751904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.
    Kumar S; Shelley M; Harrison C; Coles B; Wilt TJ; Mason MD
    Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD006019. PubMed ID: 17054269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.
    Hanks GE; Pajak TF; Porter A; Grignon D; Brereton H; Venkatesan V; Horwitz EM; Lawton C; Rosenthal SA; Sandler HM; Shipley WU;
    J Clin Oncol; 2003 Nov; 21(21):3972-8. PubMed ID: 14581419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial.
    Ray ME; Bae K; Hussain MH; Hanks GE; Shipley WU; Sandler HM
    J Natl Cancer Inst; 2009 Feb; 101(4):228-36. PubMed ID: 19211454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. National practice patterns and time trends in androgen ablation for localized prostate cancer.
    Cooperberg MR; Grossfeld GD; Lubeck DP; Carroll PR
    J Natl Cancer Inst; 2003 Jul; 95(13):981-9. PubMed ID: 12837834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
    Widmark A; Klepp O; Solberg A; Damber JE; Angelsen A; Fransson P; Lund JA; Tasdemir I; Hoyer M; Wiklund F; Fosså SD; ;
    Lancet; 2009 Jan; 373(9660):301-8. PubMed ID: 19091394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer.
    Witjes WP; Schulman CC; Debruyne FM
    Urology; 1997 Mar; 49(3A Suppl):65-9. PubMed ID: 9123739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy.
    Corn BW; Valicenti RK; Mulholland SG; Hyslop T; Gomella L
    Urology; 1998 May; 51(5):782-7. PubMed ID: 9610592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy?
    Pai HH; Eldridge B; Bishop D; Alexander A; Lesperance M; Blood P; Lim J; Ludgate C
    Can J Urol; 2009 Apr; 16(2):4541-52. PubMed ID: 19364426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer.
    Crook J; Ludgate C; Malone S; Perry G; Eapen L; Bowen J; Robertson S; Lockwood G
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):327-33. PubMed ID: 18707821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer.
    Lamb DS; Denham JW; Mameghan H; Joseph D; Turner S; Matthews J; Franklin I; Atkinson C; North J; Poulsen M; Kovacev O; Robertson R; Francis L; Christie D; Spry NA; Tai KH; Wynne C; Duchesne G
    Radiother Oncol; 2003 Sep; 68(3):255-67. PubMed ID: 13129633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
    Parker CC; Clarke NW; Cook AD; Kynaston H; Catton CN; Cross WR; Petersen PM; Persad RA; Saad F; Bower LC; Logue J; Payne H; Forcat S; Goldstein C; Murphy C; Anderson J; Barkati M; Bottomley DM; Branagan J; Choudhury A; Chung PWM; Cogley L; Goh CL; Hoskin P; Khoo V; Malone SC; Masters L; Morris SL; Nabid A; Ong AD; Raman R; Tarver KL; Tree AC; Worlding J; Wylie JP; Zarkar AM; Parulekar WR; Parmar MKB; Sydes MR;
    Lancet; 2024 Jun; 403(10442):2405-2415. PubMed ID: 38763154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.